Showing results (151-160 of 535) with videos related to
Sort By:
Pageof 54
The Journal of Biological Chemistry|September 5, 1990
Hepatic P-450 cholesterol 7 alpha-hydroxylase. Regulation in vivo at the protein and mRNA level in response to mevalonate, diurnal rhythm, and bile acid feedbackS S Sundseth, D J WaxmanCancer Research|January 13, 2012
VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regressionJoshua C Doloff, David J WaxmanJournal of Immunology (Baltimore, Md. : 1950)|January 7, 2000
Glomerular deposition of immune complexes made with IgG2a monoclonal antibodiesM L Gonzalez, F J WaxmanClinical Immunology (Orlando, Fla.)|August 22, 2001
Relationship between complement activation and renal deposition of immune complexes made with IgG2a monoclonal antibodiesM L Gonzalez, F J WaxmanThe Journal of Biological Chemistry|April 5, 1990
Regulation and ligand-binding specificities of two sex-specific bile acid-binding proteins of rat liver cytosolG A LeBlanc, D J WaxmanAnti-Cancer Agents in Medicinal Chemistry|July 23, 2013
Adenoviral vectors for prodrug activation-based gene therapy for cancerJoshua C Doloff, David J WaxmanClinical Oncology (Royal College of Radiologists (Great Britain))|June 28, 2008
Reovirus: viral therapy for cancer 'as nature intended'C Comins, L Heinemann, K Harrington, et al.Prostate Cancer and Prostatic Diseases|August 4, 2005
Phase II study of oral capecitabine in patients with hormone-refractory prostate cancerJ Spicer, T Plunkett, N Somaiah, et al.Clinical and Experimental Immunology|October 23, 2004
The common heat shock protein receptor CD91 is up-regulated on monocytes of advanced melanoma slow progressorsJ Stebbing, M Bower, B Gazzard, et al.The Journal of Urology|May 19, 2007
Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II studyR Lord, S Nair, A Schache, et al.Pageof 54